This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taylor, L. Articles by Schwarz, H. Search for Related Content PubMed PubMed Citation Articles by Taylor, L. Articles by Schwarz, H.

(Journal of Leukocyte Biology. 2002;72:522-529.)
© 2002 by Society for Leukocyte Biology

In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions

Liz Taylor^*, Marcus Bachler, Imogen Duncan^*, Simon Keen^*, Rosie Fallon^*, Catherine Mair^*, Thomas T. McDonald and Herbert Schwarz^*

^* Xenova Group plc, Cambridge, United Kingdom; and
Division of Infection, Inflammation and Repair, University of Southampton, United Kingdom

Correspondence: Herbert Schwarz, Xenova Group, 310 Cambridge Science Park, Cambridge CB4 OWG, UK. E-mail: herbert_schwarz{at}xenova.co.uk

Recombinant fusion proteins consisting of the extracellular domain of immunoregulatory proteins and the constant domain of immunoglobulin G (IgG) are a novel class of human therapeutics. IgG isoforms exert different levels of immune effector functions, such as complement lysis and antibody-dependent cell cytotoxicity (ADCC). Several OX40-Ig fusion proteins were generated and compared in their potency to inhibit immune reactions. OX40-IgG fusion proteins act as decoys and inhibit T cell costimulation and extravasation induced by OX40 ligand-expressing antigen-presenting cells (APC) and vascular endothelial cells, respectively. In addition, OX40-IgG1 protein induces ADCC and complement lysis in OX40 ligand-expressing cells. Replacement of the IgG1 by the IgG4 domain (OX40-IgG4) eliminated complement lysis and reduced ADCC by half. Mutation of Leu²³⁵ to Glu in IgG4 eliminated the remaining ADCC activity and generated a protein devoid of immune effector functions (OX40-IgG4mut). In vitro, OX40-IgG1 was more potent in inhibiting proliferation and cytokine release by peripheral blood mononuclear cells than OX40-IgG4mut, as OX40-IgG1 induced cell death in APC. However, both proteins reduced T cell-mediated colitis in mice to the same extent, indicating that in vivo neutralization of OX40L is sufficient. This study also demonstrates that effector functions of antibodies are retained and can be rationally designed in receptor-IgG fusion proteins.

Key Words: ADCC • complement lysis • colitis

This article has been cited by other articles:

				B. E. Burrell, G. Lu, X. C. Li, and D. K. Bishop OX40 Costimulation Prevents Allograft Acceptance Induced by CD40-CD40L Blockade J. Immunol., January 1, 2009; 182(1): 379 - 390. [Abstract] [Full Text] [PDF]

				E. Roosnek, P. Schneider, and B. Huard Heparan sulfate proteoglycans, Fc receptors, and DC suppression Blood, August 1, 2008; 112(3): 915 - 916. [Full Text] [PDF]

				A. D. Weinberg, D. E. Evans, C. Thalhofer, T. Shi, and R. A. Prell The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement J. Leukoc. Biol., June 1, 2004; 75(6): 962 - 972. [Abstract] [Full Text] [PDF]

				I. R. Humphreys, G. Walzl, L. Edwards, A. Rae, S. Hill, and T. Hussell A Critical Role for OX40 in T Cell-mediated Immunopathology during Lung Viral Infection J. Exp. Med., October 20, 2003; 198(8): 1237 - 1242. [Abstract] [Full Text] [PDF]

				J. Wilson, C. P. Rossi, S. Carboni, C. Fremaux, D. Perrin, C. Soto, M. Kosco-Vilbois, and A. Scheer A Homogeneous 384-Well High-Throughput Binding Assay for a TNF Receptor Using Alphascreen Technology J Biomol Screen, October 1, 2003; 8(5): 522 - 532. [Abstract] [PDF]